Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC/VI vs Tiotropium in Symptomatic COPD
NCT01899742Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of umeclidinium and vilanterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change From Baseline in Trough Forced Expiratory Volume in One Second at Day 85. Started Sep 2014; status: completed.
02
Drugs
umeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01899742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01899742.